sees q3 revenue $400 million to $500 million.
reaffirms 2021 full year forecast for revenues and profit.
emergent biosolutions - in quarter, inventory write-offs related to raw materials, in-process batches manufactured at bayview facility.
emergent biosolutions - fy other product sales, expected to be impacted on assumption that a new raxibacumab contract to be awarded later than planned.
